HSBC Downgrades Shire to Sell

By Ryan Adsit

In a report released today, Steve McGarry from HSBC downgraded Shire (NASDAQ: SHPG) to Sell. The company’s shares opened today at $187.51.

McGarry has an average return of 7.1% when recommending Shire.

According to TipRanks.com, McGarry is ranked #3066 out of 4560 analysts.

Shire has an analyst consensus of Moderate Buy, with a price target consensus of $236.67.

Shire’s market cap is currently $57.36B and has a P/E ratio of 273.89. The company has a book value ratio of 1.9274.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Shire Plc is a biopharmaceutical company. The company focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. The company’s products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr and foznol. Shire was founded in 1986 and is headquartered in Dublin, Ireland.